Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

Is the FIBROSpect II® index effective for determining the stage of fibrosis in patients with chronic hepatitis C?

Nature Clinical Practice Gastroenterology & Hepatology volume 5, pages 138–139 (2008)Cite this article

boxed-textZaman A et al. (2007) Assessment of FIBROSpect II to detect hepatic fibrosis in chronic hepatitis C patients. Am J Med 120: 9–14

Background

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Patel K et al. (2004) Evaluation of a panel of non-invasive serum markers to differentiate mild from moderate-to-advanced liver fibrosis in chronic hepatitis C patients. J Hepatol 41: 935–942

    Article  CAS  Google Scholar 

  2. Christensen C et al. (2006) Diagnostic accuracy of a fibrosis serum panel (FIBROSpect II) compared with Knodell and Ishak liver biopsy scores in chronic hepatitis C patients. J Viral Hep 13: 652–658

    Article  CAS  Google Scholar 

  3. Snyder N et al. (2007) The APRI may be enhanced by the use of the FIBROSpect II in the estimation of fibrosis in chronic hepatitis C. Clinica Chimica Acta 381: 119–123

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Rachel Jones, Associate Editor, Nature Clinical Practice.

Author information

Author notes

  1. Department of Gastroenterology, Brooke Army Medical Center, 3851 Roger Brooke Drive, Fort Sam Houston, TX 78234, USA stephen.harrison@amedd.army.mil

Authors and Affiliations

  1. SA Harrison is Chief of Hepatology at Brooke Army Medical Center, and Associate Professor of Medicine at the University of Texas Health Science Center, San Antonio, TX, USA.,

    Stephen A Harrison

Authors
  1. Stephen A Harrison
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Competing interests

The author declares no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Harrison, S. Is the FIBROSpect II® index effective for determining the stage of fibrosis in patients with chronic hepatitis C?. Nat Rev Gastroenterol Hepatol 5, 138–139 (2008). https://doi.org/10.1038/ncpgasthep1035

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpgasthep1035

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing